IFIH1 and interstitial lung disease: In contrast, the presence of the anti-MDA5 antibody defines a high-risk subgroup for developing rapidly progressive ILD, a fulminant complication with high mortality, which can occur even in patients with little to no muscle weakness (amyopathic DM) [23].